All In Biotech

Drug Trial Radar · NCT04297995

Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors

Evaluate the Efficacy and Safety of HLX10, PD-1 mAb, in Combination With HLX07, EGFR mAb, in Patients With Advanced Head And Neck Tumors

Last checked: Nov 19, 2026Latest source record: Aug 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 131 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

131

Planned (sponsor's estimate)

Start

Jul 29, 2020

Primary completion

May 30, 2024

Study completion Jun 30, 2025

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Mar 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Part1: A mutilpe-center, open-label, Phase II clinical trial to evaluate the efficacy and the safety of HLX10 in combination with HLX07 in patients with advanced advanced head and neck tumors. Part2: A randomized, double-blind, multi-center, phase II clinical study to evaluate the clinical efficacy and safety of HLX10 in combination with HLX07 and chemotherapy versus HLX10 in combination with placebo and chemotherapy in the first-line treatment of R/M HNSCC.

Conditions

  • Head and Neck Squamous Cell Carcinoma

Interventions

  • HLX10Drug

    Part 1: HLX10 3 mg/kg biweekly. Part 2: HLX10 300 mg every three weeks.

  • HLX07Drug

    Part 1: HLX07 600 mg weekly (stage 1L). Part 1: HLX07 800 mg weekly (stage 1H). Part 2: HLX07 1000 mg every three weeks.

  • HLX07 placeboDrug

    HLX07 placebo 1000 mg every three weeks

  • Cisplatin/CarboplatinDrug

    Cisplatin 100 mg/m2 every three weeks. Cisplatin will be switched to carboplatin in case of intolerance to cisplatin. Up to 6 cycles.

  • 5-FUDrug

    5-FU 1000 mg/m2/day, 1-4 days, every three weeks. Up to 6 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part1: Efficacy-ORRTime frame: at 16 weeks after first dose
  2. Part1: Safety-adverse event profileTime frame: up to one year
  3. Part2: Efficacy-ORR (IRRC)Time frame: at 3 months after first dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Henlius Biotech Inc.

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.